Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
maybe the .27 buyout does get a no vote? gapped so people must think so
I do think this is interesting and have been fence sitting... maybe too long ;)
Yep, but from what I've figured out so far, there's a very good likelihood, "Ain't gonna happen". JMO, and I have not made an entry yet. Waiting on funds clearing from another stock sale and watching in the meantime. Considering this one and another ticker. Looks like this could do really well, if it does not happen.
10 mil Float.
Breaking Edge (and desperately needed)FAST RESULT Ebola test
Stem Cell Tech too
Possible Buy out would only make this more attractive, if it doesn't go through (for the right reasons)and if they don't dilute or go toxic finance
Not much not to like here, but IF I enter, it'll be for less than .27 and put less than a grand in it.
Uh have you read about the .27 buyout??
That article is what brought me here.....Looks interesting, but it also looks like the "Stem Cell Technology" they are referring to is similar & may be patented by another company (SVF*), although this company isn't giving out the details concerning this "Stem Cell Procedure"... Could be a problem on the Stem Cell side down the road, but I love the possibilities with the Ebola test. I'm here to see if there is a 300% gain. Just being honest here. GLTA here.
Interesting article on yahoo:
http://news.yahoo.com/simple-new-test-finds-ebola-in-15-minutes--could-be--gamechanger--200026694.html
say what???, "The Company also incurred approximately $600,000 in expenses associated with its review of strategic alternatives and definitive agreement to be acquired by Orgentec Diagnostika"
Another part of that merger agreement that makes you wonder about what will happen and about that out of nowhere volume a couple days ago.
thanks >>>>>>>your video were very interesting (( finding in 10 minutes time
unit cost $5000
once mass productiont from $500 to $20=$50
wonderful product for ebola tesing kit . we need it fast before going banna in u.s.a
more ebola coming into u.s.a president is a joke on this matter
need temporay ban travelling from w/africa untill control the ebola???????
from uk too simple and cheapie with in 90 minutes finding ebola
http://www.domain-b.com/technology/Health_Medicine/20141015_ebola_test.html
Folks check this. Nice small tester for Ebola.
http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3841659343001
EXACTLY!!! I'm betting the merger will NOT go through!
Meaning dollar land for CONX pretty soon!
gm to u sir kicking in pre/m $_ coming
Alot in that merger agreement, closing conditions, and subsequent documents that make you wonder how they are even going to close the merger deal. Based on doing initial DD, after seeing that volume spike today, not sure the market is pricing in the possibility that this merger won't be realized. Seems market may just be starting to pricing in the potential significant upside if deal falls through, versus the more limited downside risk. Could be in dollar land and beyond if there is no merger, down to .27 if there is. Of course, just my two cents, but that's not a bad bet to make.
While there is much more in those recent documents that make you wonder, here is just one of them:
http://www.sec.gov/Archives/edgar/data/1063665/000110465914063526/a14-20099_18k.htm
CONX 10 minute Ebola test kit ready to go! Obviously-Imperative that we have a fast and reliable ebola test kit made available ASAP. Hopefully slow Federal Gov't will approve CONX test kit soon.
CONX has the only one and it's ready to be produced and distributed - according to recent news
1. *Test kit - ready but waiting see above 2. vaccine- not ready
3.hazmat equip -ready but not very reliable 4. cure - Not available yet
more likly continue to be hot ebols trend now on #$=
volume today
conx and cbmc too
ebola relate stocks
drug and security suits and test kit gonna be money maker in this field
money coming fella
Interesting action with volume today (highest 1 day volume in history of stock), news coverage in past day and minimal chatter atm. Got to be alot of pressure on the BOD to bail on that deal. A really strange time to go through with an acquisition. If gov't speeds up approval process wouldn't be surprised if valuation shifted pretty dramatically. And would be hard to make the case for that .27. Even now at this point it definitely is, based on valuations of other stocks in area, should be way higher.
Either way, CEO and employees are still doing interviews etc. and with the latest interviews have faith that they can ramp it up quickly if government approval happens quicker. Of course, who knows, but definitely on watch.
http://rt.com/usa/196224-ebola-rapid-blood-test/
http://denver.cbslocal.com/2014/10/14/colorado-test-for-ebola-could-speed-up-diagnosis-to-10-minutes/
http://yahoo.brand.edgar-online.com/DisplayFiling.aspx?TabIndex=2&FilingID=10216229&companyid=8128&ppu=%252fDefault.aspx%253fcompanyid%253d8128%2526amp%253bformtypeID%253d290
Company: CORGENIX MEDICAL CORP/CO (CONX)
Form Type: PREM14A
Filing Date: 9/24/2014
CIK: 0001063665
Address: 11575 MAIN STREET
City, State, Zip: BROOMFIELD, Colorado 80020
Telephone: 303-457-4345
Fiscal Year: 06/30
Register for EDGAR Pro and access this filing in:
FORM PREM14A
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
PROPOSAL ONE - THE MERGER
Preparation of Proxy Statement; Shareholders Meeting
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
BENEFICIAL OWNERS
PROPOSAL TWO - COMPENSATION ARRANGEMENTS FOR OUR NAMED ...
PROPOSAL THREE - ADJOURNMENT OF THE SPECIAL MEETING
FUTURE SHAREHOLDER PROPOSALS
BENEFICIAL OWNERS
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10216229-90090-273626&type=sect&TabIndex=2&companyid=8128&ppu=%252fDefault.aspx%253fcompanyid%253d8128%2526amp%253bformtypeID%253d290
THE LAWYERS ARE IN DALLAS...SO YOU KNOWWWWWW THEY SMELL THE MONEY BY NOT GOING PRIVATE!
I concur on lack of cognizance of mind
However I am hopeful they prevail with lawyers and does not go through
http://www.bizjournals.com/prnewswire/press_releases/2014/09/03/DA03888
The total assets and revenue multiples are below the averages of comparable transactions, according to Bloomberg. Stock closed at $0.461 three weeks ago. Corgenix shareholders will receive only $.027 in cash for each share of common stock they own, in a transaction valued at approximately $16 million. The per-share price represents a 29% premium to the Corgenix average share price of $0.21 over strategic alternatives - See more at: http://www.dunnamlaw.com/CONX/#sthash.FGjZHzHP.dpuf
If true,,,,,,THEY NEVER WOULD HAVE SOLD THE COMPANY IN THE FIRST DAMM PLACE!! SORRY BUT THIS CEO IS AN IDIOT!!!!
THEY ARE IN TEXAS: http://www.dunnamlaw.com/CONX/ WEEEEEEEEEEEEE! SHOULD RUN HARD TOMORROW.
THE DEAL TO SELL MIGHT NOT GO THROUGH:
Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to ...
Corgenix Medical Corp. (QB) (USOTC:CONX)
Historical Stock Chart
1 Month : From Sep 2014 to Oct 2014
Click Here for more Corgenix Medical Corp. (QB) Charts.
NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika. Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.
The law firm is investigating because the total assets and revenue multiples are below the averages of comparable transactions, according to Bloomberg. Additionally, the stock closed at $0.461 three weeks ago. Corgenix shareholders will receive only $.027 in cash for each share of common stock they own, in a transaction valued at approximately $16 million.
Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. CONX stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at hlindley@dunnamlaw.com with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/CONX.
SOURCE Dunnam & Dunnam
*********EBOLA FOUND IN TEXAS************
That is a given, class action attorneys will be licking their chops and for good reason. And guess who will pay to defend them, the shareholders. I will sign on with that suit when it does happen, that is certain. What complete idiots. It is time to block the deal and sweep the management deck entirely....and I mean down to the girl answering the phone at the front desk. I would rather see my stock go to a dime and rebuild with a new team than see these management clowns cash out with millions from the options they issued themselves for a nickel or so. This is theft IMO.
I see a potential class action suit coming for this buyunder.
Corgenix Enters into Agreement to Be Acquired by Orgentec Diagnostika
Corgenix shareholders to receive $0.27 in cash
Transaction valued at approximately $16 million
Following the transaction, Corgenix will remain headquartered in Broomfield, Colo. as a subsidiary of Orgentec Diagnostika
Strategic Acquisition Creates Leading Global Specialty Diagnostics Company
Business Wire Corgenix Medical Corporation
44 minutes ago
DENVER--(BUSINESS WIRE)--
Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has entered into a definitive merger agreement to be acquired by Orgentec Diagnostika, a leading specialty diagnostics company headquartered in Mainz, Germany. The strategic acquisition will extend both companies’ global distribution network and broaden their portfolio of specialty diagnostic assays.
Under the terms of the agreement, which has been approved unanimously by Corgenix’s Board of Directors, Corgenix shareholders will receive $0.27 in cash for each share of common stock they own, in a transaction valued at approximately $16 million. The per-share price represents a 29% premium to the Corgenix average share price of $0.21 over the 90-day period prior to the Company’s announcement on March 12, 2014, that it was exploring strategic alternatives.
Together, Orgentec and Corgenix will offer more than 350 tests, primarily enzyme-linked immunosorbent assays (ELISA), that diagnose a range of conditions, including autoimmune, vascular, infectious disease and organ function. As a combined company, they will serve thousands of hospitals and reference laboratories throughout Europe and the U.S., as well as the emerging markets of Asia, Latin America and the Middle East.
“The Corgenix brand is very respected in our industry space, and this transaction provides excellent value to Corgenix shareholders,” said Corgenix President and CEO Douglass Simpson. “After a robust auction process and a thorough review of all alternatives, including staying as an independent company, the Company’s Board of Directors strongly believes that acceptance of the Orgentec offer is the best choice to maximize our shareholders’ value.”
Werner Hofacher, CEO of Orgentec, added, “Our agreement with Corgenix is an important step toward achieving our strategy of building Orgentec into a global specialty diagnostics leader. It will give us an immediate direct presence in the United States, where Corgenix is highly regarded for its quality and innovation. Together, we will offer a unique portfolio of complementary tests and automated instruments that help health care providers diagnose rare conditions and diseases across key medical specialties.”
The agreement to acquire Corgenix is Orgentec’s first significant step toward expanding its position in the global specialty diagnostics market since partnering with Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Orgentec, which was founded in 1988, announced its partnership with Water Street in May 2014.
“Corgenix is a key component of Water Street’s strategic plan to build Orgentec into a global specialty diagnostics leader,” said Scott Garrett, a senior operating partner with Water Street and chairman of Orgentec. “We will continue to invest in targeted acquisitions, and research and development initiatives that will further expand Orgentec’s strong platform of highly specialized diagnostic solutions.”
The transaction is subject to approval by Corgenix shareholders and other customary closing conditions, and is expected to close in the fourth calendar quarter of 2014.
Inverness Advisors, a division of KEMA Partners LLC, acted as financial advisor to Corgenix in connection with the transaction.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
About Orgentec
Orgentec offers a portfolio of more than 300 tests, primarily enzyme-linked immunosorbent assays (ELISA), that help diagnose rheumatology, thrombosis and gastroenterology disorders, as well as infectious diseases. It also offers a fully automated instrument and associated test kits that enable laboratories to complete multiple assays and deliver faster results than traditional ELISA tests. Orgentec has a well-established position in Europe and a growing presence in Asia, Latin America and the Middle East. Orgentec is a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. For more information, visit www.orgentec.com.
Cautionary Statement Regarding Forward-Looking Statements
We caution you that this document may contain disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about the Company and the Merger. Forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. These forward-looking statements are based upon information presently available to the Company’s management and are inherently subjective, uncertain and subject to change, due to any number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted with respect to the Merger; and the inability to complete the Merger due to the failure to obtain the shareholder approval or the failure to satisfy other closing conditions, as well as other risk factors detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, filed with the SEC on September 30, 2013 under the captions “Forward Looking Statements” and “Risk Factors” and otherwise in the Company’s reports and filings with the Securities and Exchange Commission. Many of these factors are beyond the Company’s ability to control or predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise, except as otherwise may be required by law.
Additional Information about the Merger and Where to Find It
This document may be deemed to be solicitation material with respect to the Merger. In connection with the Merger, the Company intends to file a preliminary proxy statement and file or furnish other relevant materials with the Securities and Exchange Commission (the “SEC”). Once the SEC completes its review of the preliminary proxy statement, a definitive proxy statement and a form of proxy will be filed with the SEC and mailed to the shareholders of the Company. THE COMPANY’S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The proxy statement and other relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, the Company’s investors and security holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a written request to Corgenix Medical Corporation, 11575 Main Street, Suite 400, Broomfield, Colorado 80020, Attention: William H. Critchfield.
Participants in the Solicitation
The Company and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the special meeting of shareholders that will be held to consider the Merger. Information about those executive officers and directors of the Company and their ownership of the Company’s common stock is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, which was filed with the SEC on September 30, 2013, and is supplemented by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests of the Company, its executive officers and directors and other participants in the solicitation will be set forth in the proxy statement relating to the Merger when it becomes available and may, in some cases, be different from those of the Company’s security holders generally.
Contact:
Orgentec Contact:
Kelly Zitlow, 847-858-5230
Vice President
Kelly.zitlow@waterstreet.com
or
Corgenix Contacts:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Armada Medical Marketing
Dan Snyders, 303-623-1190 x230
Vice President and Public Relations Supervisor
dan@armadamedical.com
Good 8k out today & no action?
If I'm correct 10q should be out this week and show some good revenue. This is going to take off.
I guess the CONX promotion didn't quite work out as expected
http://www.otcdynamics.com/$conx-corgenix-medical-corp-promotional-campaign-starting-aug-4-2014-1006-am-cst/
Yup 13% sell off so far, HUGE!!
Dude I have no idea what you're talking about...no hidden agenda read the news. HENCE THE SELL OFF
Yup, $11k bidding 44
Ok, you obviously sold so good luck in your next trade. I'd rather be in b 4 the pr with approval comes and chase. Everyone has their strategy. If it drops I'll buy more. He prolly cautioned so he can do his insider buying, lol. GLTY
CONX more than double avg daily volume already, volume precedes pps
HEED THE OWN WORDS OF THE CEO...HE CAUTIONED INVESTORS NOT TO BELIEVE MEDIA REPORTS!!!! AND I BELIEVE HIM....
Lol yeah well they can't tell u how close.
"They're getting close" KEY WORDS....NO CIGARS FOR CLOSE WINNERS AND LOSERS.
Tulane university believes in them, it's been nearly three years already. If they're research is funded then their getting close IMO. With the new sense of urgency it will be approved quicker:
In the past, Corgenix has served as a subcontractor to Tulane University for several NIH-funded grants and contracts related to development of diagnostics, vaccines and therapeutics for hemorrhagic fever viruses such as Lassa, Ebola and Marburg. Corgenix currently serves as the principal investigator for the new NIH-funded three-year contract to complete the development of recombinant diagnostic tests for Ebola.
The most recent grant was awarded to Corgenix and members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. The NIH phase II, R44 grant was awarded to Corgenix and VHFC to develop rapid diagnostic tests (RDT) for Ebola, enabling rapid response to public health and bioterrorism threats posed by the deadly virus. Corgenix and the VHFC have previously developed and CE marked the ReLASV® rapid test for the Lassa fever virus.
I don't have time for those silly games...READ TODAY'S PR!
Lol, u sold and want back in cheaper?
yeah showed great strength. 60 trades in the first 15 minutes and already double daily avg volume
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
457
|
Created
|
02/12/08
|
Type
|
Free
|
Moderators |
Blockbuster News:
CHICAGO — July 30, 2014 — Corgenix Medical Corporation (OTC BB: CONX.OB) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the conference by Corgenix Research Associate Abby Jones, M.S.
See more here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |